• Explore /
  • Poster
  • / A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.

A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.

Abstract Poster

Authors

null

Fei Ma

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Fei Ma , Nong Xu , Huoling Tang , Yuhong Zhou , Ziping Wei , Pamela N. Munster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT 04257110

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3029)

DOI

10.1200/JCO.2023.41.16_suppl.3029

Abstract #

3029

Poster Bd #

227

Abstract Disclosures

Similar Posters

Poster

2020 Gastrointestinal Cancers Symposium

Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.

First Author: Jifang Gong

First Author: Gary Edward Richardson

First Author: Johanna C. Bendell

First Author: Andrae L. Vandross